| pubmed-article:18322177 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C0206394 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C0206397 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C1623051 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C1705822 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C1541478 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:18322177 | lifeskim:mentions | umls-concept:C0442821 | lld:lifeskim |
| pubmed-article:18322177 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18322177 | pubmed:dateCreated | 2008-3-6 | lld:pubmed |
| pubmed-article:18322177 | pubmed:abstractText | Delivery of tumor-associated Ag-derived peptides in a high immunogenic form represents one of the key issues for effective peptide-based cancer vaccine development. We report herein the ability of nonpathogenic filamentous bacteriophage fd virions to deliver HLA-A2-restricted MAGE-A10(254-262)- or MAGE-A3(271-279)-derived peptides and to elicit potent specific CTL responses in vitro and in vivo. Interestingly, human anti-MAGE-A3(271-279)-specific CTLs were able to kill human MAGE-A3(+) tumor cells, even if these cells naturally express a low amount of MAGE-A3(271-279) peptide-HLA epitope surface complexes and are usually not recognized by CTLs generated by conventional stimulation procedures. MAGE-A3(271-279)-specific/CD8(+) CTL clones were isolated from in vitro cultures, and their high avidity for Ag recognition was assessed. Moreover, in vivo tumor protection assay showed that vaccination of humanized HHD (HLA-A2.1(+)/H2-D(b+)) transgenic mice with phage particles expressing MAGE-A3(271-279)-derived peptides hampered tumor growth. Overall, these data indicate that engineered filamentous bacteriophage virions increase substantially the immunogenicity of delivered tumor-associated Ag-derived peptides, thus representing a novel powerful system for the development of effective peptide-based cancer vaccines. | lld:pubmed |
| pubmed-article:18322177 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18322177 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18322177 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18322177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18322177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18322177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18322177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18322177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18322177 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18322177 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18322177 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:18322177 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:SantoniAngela... | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:SartoriusRoss... | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:VelottiFrance... | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:D'ApiceLucian... | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:RomanoChiaraC | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:CorteseGianca... | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:GiorginiAngel... | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:PisuPaolaP | lld:pubmed |
| pubmed-article:18322177 | pubmed:author | pubmed-author:PizzellaLucia... | lld:pubmed |
| pubmed-article:18322177 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18322177 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18322177 | pubmed:volume | 180 | lld:pubmed |
| pubmed-article:18322177 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18322177 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18322177 | pubmed:pagination | 3719-28 | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:meshHeading | pubmed-meshheading:18322177... | lld:pubmed |
| pubmed-article:18322177 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18322177 | pubmed:articleTitle | The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. | lld:pubmed |
| pubmed-article:18322177 | pubmed:affiliation | Institute of Protein Biochemistry, Consiglio Nazionale delle Ricerche, Naples, Italy. | lld:pubmed |
| pubmed-article:18322177 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18322177 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:4109 | entrezgene:pubmed | pubmed-article:18322177 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18322177 | lld:pubmed |
